A panreactive antibody screen and a reactive autocontrol in a patient with a falling hemoglobin raise the question of warm autoimmune hemolytic anemia (WAIHA). WAIHA is the most common autoimmune hemolytic anemia in adults. An IgG autoantibody reacts near 37 °C, coats the patient's red cells, and promotes their removal by splenic and hepatic macrophages. Complement may add to the coating and accelerate clearance.1,2
Warm autoimmune hemolytic anemia
WAIHA may be primary or associated with an autoimmune disease, lymphoid malignancy, infection, immune deficiency, or another condition. About half of adult cases have an associated condition. The hemolysis can develop gradually or produce a rapid, severe anemia.1,3
The laboratory pattern of WAIHA is hemolysis with a warm-reactive autoantibody, usually with a direct antiglobulin test (DAT) positive for IgG with or without C3d, once alloimmune, drug-induced, clinically significant cold, mixed, and nonimmune causes are considered. A C3d-only DAT can occur in WAIHA. When it does, exclude a clinically significant cold antibody. DAT positivity without hemolysis does not define AIHA.1,3,4
The laboratory first establishes shortened red-cell survival. Increased indirect bilirubin and lactate dehydrogenase (LDH), decreased haptoglobin, reticulocytosis, polychromasia, and spherocytes support hemolysis. Reticulocytopenia can occur early or with nutritional deficiency, renal disease, infection, marrow disease, or rare antibody effects on erythroid precursors. An inadequate reticulocyte response during severe anemia indicates increased urgency because marrow production is not keeping pace with destruction.1,3
Interpret hemolysis evidence and the monospecific DAT pattern together. The diagnostic framework lesson describes that sequence. The Blood Group Immunology lesson explains IgG behavior, antihuman globulin testing, and complement deposition.
Most WAIHA samples have red cells coated with IgG, with or without C3d. Warm autoantibodies usually react broadly with reagent red cells at the indirect antiglobulin test (IAT) phase because their target is present on most common cells. Reaction strength varies by method. Disease activity and severity are assessed from hemolysis findings.2,3,5
IgG-coated red cells are cleared mainly outside the circulation. Splenic macrophages bind IgG Fc regions and may remove part of the membrane, leaving spherocytes with reduced deformability. Macrophages also bind complement fragments. Antibody density, IgG subclass, complement, macrophage activity, and marrow compensation together determine the severity.1,2
Immunohematologic evaluation
A warm autoantibody can react with the antibody screen, identification panel, autocontrol, and donor cells. This broad pattern can mask an alloantibody formed after transfusion or pregnancy. The transfusion and pregnancy history, previous antibody records, DAT, serum or plasma testing, and eluate findings determine the next studies.2,5
Scroll sideways to see all columns
| Study | Main question | Interpretation and limits |
|---|---|---|
| Monospecific DAT | Are IgG, C3d, or both coating the patient's red cells? | IgG with or without C3d supports a warm pattern when hemolysis is present. Recent transfusion, a drug, passive antibody, and other causes of sensitization remain in the differential. |
| Antibody screen and identification | Is broad warm reactivity present in plasma, and could an alloantibody be hidden? | Panreactivity at the IAT phase with a reactive autocontrol supports an autoantibody. Assess for a masked alloantibody. |
| Eluate | What IgG can be recovered from the patient's coated red cells? | A broadly reactive eluate supports a warm autoantibody. Specific reactivity can represent an alloantibody coating recently transfused cells. A nonreactive eluate against untreated cells can support a drug-dependent pattern when the exposure and hemolysis fit, but it is not diagnostic. |
| Red-cell phenotype or genotype | Which antigens does the patient carry, and which alloantibodies could form? | Serologic phenotyping is limited by recent transfusion and a strong DAT. Genotyping can supply a predicted antigen profile when those limits apply, although variants can differ from the predicted antigen expression. |
| Adsorption | Does plasma contain an alloantibody after broad autoantibody is removed? | Autologous adsorption uses patient cells only when the patient has not been transfused within the preceding 3 months and sufficient patient cells are available. Allogeneic adsorption or reference-laboratory testing is used when donor cells may still be circulating or patient cells are insufficient. The goal is to detect any underlying alloantibody. Broad autoantibody reactivity may still prevent a compatible crossmatch. |
Adsorption, elution, chemical cell treatment, and genotyping follow validated procedures. The method changes which antigens remain detectable and which antibodies can be excluded. Repeated adsorption also dilutes the specimen and can weaken an alloantibody. State the studies completed and the residual risk in the final interpretation.2,5
Warm IgG usually does not directly agglutinate cells in routine ABO and D typing. Resolve a reactive control or ambiguous D result by a validated method. Until the D type is resolved, local policy may direct selection of D-negative red cells. Broad Rh reactivity, a suspected antibody to a high-prevalence antigen, or another complex pattern warrants reference-laboratory support.2,5
Transfusion support
Early communication gives the clinical service the testing status, expected completion time, historical antibodies, and available unit options. It also gives the transfusion service the current hemoglobin trend, symptoms, pregnancy and transfusion history, and urgency.5
When time permits, the laboratory excludes clinically significant alloantibodies and selects ABO-compatible red cells that lack antigens for current and historically documented clinically significant alloantibodies. A patient antigen profile can guide Rh and K matching and broader matching when indicated by prior antibodies or ongoing transfusion needs. The autoantibody may continue to react with every donor unit after this work is complete.2,5
The phrase "least incompatible" is obsolete. Crossmatch reaction grades against a broadly reactive autoantibody do not identify a safer unit. Unit selection is based on alloantibody assessment, antigen matching, testing limits, and the documented reason for release.5
When the clinical service reports that transfusion cannot wait for lengthy adsorption or molecular studies, the transfusion service may issue emergency-release group O red cells under local policy. Known clinically significant alloantibodies guide antigen-negative selection when suitable units can be supplied without a dangerous delay. The laboratory communicates the testing limit and release basis. The clinical service determines transfusion need from symptoms, hemodynamic status, comorbidities, and the hemoglobin trend.2,3,5
The clinical service directs treatment. The laboratory monitors hemolysis, defines the immune pattern, searches for an alloantibody, and supplies the safest available red cells when transfusion is ordered.1,3
Mixed and routine-DAT-negative AIHA
Mixed AIHA requires evidence of both a warm autoantibody and a clinically important cold autoantibody. An IgG-and-C3d DAT pattern is a starting point for the evaluation. Warm IgG can also activate complement, so C3d on the cells does not establish a cold component. A broadly reactive warm eluate or IAT pattern supports the warm component after the transfusion, pregnancy, and alloantibody context is assessed. Cold reactivity at or above 30 °C is a widely used convention for a pathologic cold component, and laboratory-specific interpretation remains necessary. When thermal testing is unavailable, a titer of at least 1:64 at 4 °C is supporting evidence only when interpreted with the complete serologic pattern.3,6
Scroll sideways to see all columns
| Pattern | Routine findings | Laboratory response |
|---|---|---|
| Mixed AIHA | Hemolysis; DAT positive for IgG and C3d; warm reactivity supported in eluate or plasma after alloantibody assessment; cold agglutinin with clinically important thermal range | Characterize both components, control cold interference, and assess masked alloantibodies before unit selection |
| Routine-DAT-negative AIHA | Convincing hemolysis with nonreactive routine anti-IgG and anti-C3d testing after other causes are assessed | Repeat testing on a fresh EDTA specimen under a validated method, add specialized reagents when available, and refer persistent unexplained cases |
| Warm IgM AIHA | Warm-reactive IgM may produce spontaneous agglutination and strong complement coating despite weak routine findings | Resolve typing interference under a validated method and refer persistent or atypical cases for specialized testing that can detect cell-bound IgM |
Common explanations for routine-DAT-negative WAIHA include IgG below the method's detection limit, low-affinity IgG that dissociates during washing, and red-cell-bound IgA or IgM that routine anti-IgG and anti-C3d do not directly detect. Reference laboratories can use expanded monospecific reagents, column methods, flow cytometry, or quantitative cell-bound immunoglobulin assays. Sensitive methods can reduce specificity, and some cases remain nonreactive across available assays. Report this pattern only with objective hemolysis, assessment of alternative causes, and the complete clinical and serologic pattern.3,7
Thermal range and the DAT pattern distinguish these disorders from cold agglutinin disease. Cold agglutinins are usually IgM that bind best at 4 °C, and clinically important cold reactivity often extends toward physiologic temperatures. The DAT in cold agglutinin disease is usually strongly C3d positive with IgG absent or weak. Interpretation also requires evidence of hemolysis and the complete serologic pattern. The complement-coated cells are cleared mainly outside the circulation by hepatic macrophages. Warm IgG reacts near 37 °C, and its coated cells are cleared by splenic and hepatic macrophages, a pattern that also describes mixed AIHA and routine-DAT-negative WAIHA.2,3
Drug-induced immune hemolytic anemia
Drug-induced immune hemolytic anemia (DIIHA) is rare and ranges from compensated hemolysis to abrupt intravascular destruction. A drug investigation is warranted when immune hemolysis has a plausible timing relationship to an exposure and more common causes have been assessed. An isolated positive DAT is not sufficient. Take a medication history that includes prescription and over-the-counter drugs, inpatient and perioperative doses, prior exposure, and recently discontinued drugs.8,9
Antibiotics account for many reported cases. Examples with substantial laboratory evidence include piperacillin, ceftriaxone, cefotetan, and penicillin. Diclofenac and oxaliplatin are important examples from other drug classes. The drugs encountered vary with prescribing patterns and the population studied. A reported association is a reason to investigate. The patient's hemolysis, exposure timing, serology, and competing causes determine the case interpretation.9-11
Current laboratory classification separates drug-dependent antibodies, drug-independent antibodies, and drug-associated nonimmunologic protein adsorption. Historical names such as "hapten" and "immune complex" remain useful shorthand for test patterns, although the mechanisms overlap.8,10
Scroll sideways to see all columns
| Pattern | Serologic behavior | Typical laboratory clue | Hemolysis pattern |
|---|---|---|---|
| Drug-dependent antibody against firmly bound drug | Patient plasma reacts with drug-treated red cells; untreated cells may not react | Routine screen and eluate against untreated cells may be nonreactive because ordinary reagent cells lack the drug | Often IgG-mediated extravascular hemolysis; complement and other patterns can occur |
| Drug-dependent antibody detected with soluble drug | Patient plasma reacts with red cells when the drug or a relevant metabolite is present in the test system | DAT often shows C3d, with or without IgG. Routine no-drug tests may be nonreactive. Circulating drug or metabolite in the specimen can make them reactive | Complement can produce rapid intravascular hemolysis and acute kidney injury |
| Drug-independent autoantibody | Plasma and eluate react with untreated red cells without drug in the test system | Serology is indistinguishable from ordinary WAIHA | Often a warm extravascular pattern, with clinical variation |
| Nonimmunologic protein adsorption | A drug alters the red-cell membrane and permits nonspecific adsorption of immunoglobulin, albumin, or complement | DAT may be reactive without a reproducible drug-specific antibody | True hemolysis can occur, but it must be established independently of the DAT |
Laboratory investigation
- Establish immune hemolysis and its intravascular or extravascular pattern.
- Record every recent drug with dose timing, route, previous exposure, perioperative administration, and discontinuation date. Add transfusion, pregnancy, passive-antibody, and antibody-therapy history.
- Collect EDTA whole blood and serum promptly during the event, ideally before another dose or transfusion. Retain an earlier pretransfusion specimen when available.
- Perform the DAT with monospecific anti-IgG and anti-C3d and complete routine alloantibody testing.
- Use the eluate and transfusion history to assess a warm autoantibody, an alloantibody coating transfused cells, and a drug-dependent pattern. A routine screen or eluate performed without drug can be nonreactive because the antibody requires drug in the test system.
- Consult a reference laboratory when immune hemolysis has a plausible drug relationship and local testing cannot resolve the pattern, especially with abrupt intravascular hemolysis, kidney injury, recent transfusion, or C3d coating with unrevealing routine studies.
Reference testing compares the patient's sample with and without drug, using untreated and drug-treated cells plus appropriate control specimens. A relevant metabolite or ex vivo drug antigen may be required. Drug solubility, complement availability, collection timing, and method sensitivity can also affect results, so a negative native-drug study does not exclude DIIHA. Specialized findings support the diagnosis within the complete clinical and laboratory pattern.8,11
Communicate a suspected DIIHA pattern promptly, because the clinical service decides whether to stop the implicated drug and selects an alternative. Transfusion support follows the same priority used in other immune hemolytic anemias: assess alloantibodies, select antigen-negative units for any identified alloantibody, and supply emergency red cells when delay poses the greater risk.5,8
Hemolysis during ceftriaxone exposure after a recent transfusion
An adult man's hemoglobin falls from 9.8 to 6.1 g/dL over 24 hours. Lactate dehydrogenase is 1,150 U/L and indirect bilirubin is 3.2 mg/dL, both flagged high by the reporting laboratory. Haptoglobin is below the assay's reporting limit of 10 mg/dL. A separately collected specimen also shows plasma hemoglobinemia, meaning free hemoglobin in plasma. Specimen identity and collection checks reveal no error. The clinical service reports no current bleeding. These results support hemolysis with an intravascular component, so the scientist promptly communicates the fall in hemoglobin and begins an immune investigation.5,11
History and specimens. The patient received two red-cell units at another hospital 6 days earlier for blood loss that has since stopped. That hospital confirms a negative pretransfusion antibody screen and no recorded antibody history, but the earlier specimen is no longer available. Intravenous ceftriaxone was started 3 days ago, and the latest dose was given 2 hours before hemolysis was recognized. A previous course is documented. Pharmacy supplies the complete administration record, including unchanged long-term medicines and recently stopped drugs. There is no recent immunoglobulin or antibody therapy. The timing supports a drug investigation but cannot establish causation.
Ethylenediaminetetraacetic acid (EDTA) whole blood and serum are collected during the event, before any further transfusion or drug administration. The scientist records these times and retains the specimens for consultation. Without the earlier specimen, direct before-and-after serologic comparison is limited. The negative historical screen cannot exclude a newly detectable alloantibody. The receiving reference laboratory confirms specimen suitability and any additional material needed before shipment.5,12
Local serology. The DAT is positive, with anti-IgG 1+ and anti-C3d 3+. The control is nonreactive. The routine plasma antibody screen and identification panel are nonreactive at the IAT phase. An acid eluate, which contains material removed from the patient's coated red cells, does not react with untreated panel cells. The final wash control is negative and method quality checks are acceptable. No drug has been deliberately added to these routine tests.
IgG and complement coating support an immune contribution when considered with the hemolysis. They do not identify its cause. A typical warm autoantibody is less well supported because broad reactivity is absent from both plasma and eluate. Because of the recent transfusion, a delayed alloimmune reaction remains possible, although no alloantibody specificity has been demonstrated. The scientist continues the transfusion-reaction review and requests the outside compatibility and unit records. That investigation remains open because these negative local tests cannot exclude an alloantibody.5
A drug-dependent antibody could explain coating in the patient with little reactivity against untreated reagent cells. Routine testing may lack the necessary drug or metabolite. Drug remaining in a patient's sample can sometimes cause routine reactivity. The negative eluate is consistent with this possibility but does not prove it, and ceftriaxone in the medication history does not identify a ceftriaxone-dependent antibody.8,11
Interim interpretation. The local laboratory reports hemolysis with an IgG-and-C3d-positive DAT and unresolved antibody mechanism. It communicates possible drug dependence and the remaining transfusion-related concern to the transfusion medicine physician and clinical service. Reference consultation is appropriate at this point because the laboratory cannot perform validated drug-dependent antibody studies. The referral includes the event specimens, medication timeline, hemolysis results, serology, and transfusion records.5,12
Returned findings and final report. In this case, the reference laboratory demonstrates reproducible reactivity of the patient's serum with red cells in the presence of ceftriaxone, with no reactivity in the matched no-drug test. Control sera tested with ceftriaxone and the red-cell controls are nonreactive. These comparisons establish that the reaction depends on both the patient's antibody and ceftriaxone, and they exclude nonspecific reactivity of the test system. Repeat routine plasma and eluate testing identifies no warm panreactivity or alloantibody specificity. The outside hospital's unit and compatibility records show no identification or ABO compatibility error. The scientist reviews those records and the reference findings with the transfusion medicine physician before completing the report.8,11
The final interpretation is: "Ceftriaxone-dependent red-cell antibody detected. In conjunction with the documented hemolysis and exposure, the findings support ceftriaxone-induced immune hemolytic anemia. No alloantibody was detected in the studies performed." Drug-dependent reactivity explains the positive local DAT and the negative routine eluate. The evidence supports this mechanism more than a typical warm autoantibody or a transfusion-related alloantibody. Because the earlier specimen is missing and each method has limited sensitivity, the studies cannot exclude every possible concurrent antibody. A drug-dependent antibody result does not establish hemolytic anemia without the independent hemolysis findings.5,12
The scientist incorporates the reference report into the patient record, documents the completed laboratory investigation and its limitations, and communicates the final finding to the clinical service and transfusion service for future testing and compatibility review. The responsible clinical service makes medication decisions. The laboratory reports what the tests showed and what they could not exclude.
Practice
References
- Michel M, Crickx E, Fattizzo B, Barcellini W. Autoimmune haemolytic anaemias. Nat Rev Dis Primers. 2024;10(1):82. doi:10.1038/s41572-024-00566-2 Back to text
- Bloch EM, Campbell-Lee S, McKenna DH Jr, Montemayor-Garcia C, Schwartz J, Shaz B, Storry J, eds. Technical Manual. 22nd ed. AABB; 2026. Back to text
- Jäger U, Barcellini W, Broome CM, et al. Diagnosis and treatment of autoimmune hemolytic anemia in adults: recommendations from the First International Consensus Meeting. Blood Rev. 2020;41:100648. doi:10.1016/j.blre.2019.100648 Back to text
- Hill QA, Stamps R, Massey E, Grainger JD, Provan D, Hill A. The diagnosis and management of primary autoimmune haemolytic anaemia. Br J Haematol. 2017;176(3):395-411. doi:10.1111/bjh.14478 Back to text
- Johnson ST, Puca KE. Evaluating patients with autoimmune hemolytic anemia in the transfusion service and immunohematology reference laboratory: pretransfusion testing challenges and best transfusion-management strategies. Hematology Am Soc Hematol Educ Program. 2022;2022(1):96-104. doi:10.1182/hematology.2022000406 Back to text
- Jacobs JW, Raza S, Clark LM, et al. Mixed autoimmune hemolytic anemia: a systematic review of epidemiology, clinical characteristics, therapies, and outcomes. Am J Hematol. 2025;100(8):1397-1407. doi:10.1002/ajh.27721 Back to text
- Kamesaki T, Kajii E. A comprehensive diagnostic algorithm for direct antiglobulin test-negative autoimmune hemolytic anemia reveals the relative ratio of three mechanisms in a single laboratory. Acta Haematol. 2018;140(1):10-17. doi:10.1159/000488753 Back to text
- Leger RM, Arndt PA, Garratty G. How we investigate drug-induced immune hemolytic anemia. Immunohematology. 2014;30(2):85-94. doi:10.21307/immunohematology-2019-102 Back to text
- Maquet J, Lafaurie M, Michel M, Lapeyre-Mestre M, Moulis G. Drug-induced immune hemolytic anemia: detection of new signals and risk assessment in a nationwide cohort study. Blood Adv. 2024;8(3):817-826. doi:10.1182/bloodadvances.2023009801 Back to text
- Garratty G, Arndt PA. Drugs that have been shown to cause drug-induced immune hemolytic anemia or positive direct antiglobulin tests: some interesting findings since 2007. Immunohematology. 2014;30(2):66-79. doi:10.21307/immunohematology-2019-100 Back to text
- Mayer B, Bartolmäs T, Yürek S, Salama A. Variability of findings in drug-induced immune haemolytic anaemia: experience over 20 years in a single centre. Transfus Med Hemother. 2015;42(5):333-339. doi:10.1159/000440673 Back to text
- Versiti. Drug-Dependent RBC Antibody Studies. Revised October 2022. Accessed September 5, 2026. Back to text